mAbs and vaccines against Lassa Fever Virus

抗拉沙热病毒的单克隆抗体和疫苗

• 批准号: 10497755
• 负责人: NANCY J SULLIVAN
• 金额: $ 5.76万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10497755
• 关键词: Adenovirus Vector; Disease Outbreaks; Ebola; Ebola virus; Immunity; Infection; Laboratories; Lassa virus; Monoclonal Antibodies; Therapeutic; Vaccination; Vaccines; Viral Hemorrhagic Fevers; Virus Diseases; effective therapy; nonhuman primate; prevent; vaccine trial; vector vaccine

A vaccine against Lassa virus would be highly significant in preventing outbreaks which are both naturally occurring or the result of bioterrorist activity. Lassa virus has been identified as the cause of outbreaks of hemorrhagic fever for which there is no effective treatment or cure. Therefore, vaccine studies are critically important for protection against infection. We developed a highly effective vaccine strategy for Ebola virus infection in non-human primates. Our laboratory has demonstrated that protective immunity to Ebola can be generated with a single inoculation of an adenoviral vector vaccine, a result with significant implications for conducting enhanced ring vaccination during an Ebola outbreak. We aim to use a similar strategy for Lassa.

针对LASSA病毒的疫苗在防止天然发生或生物恐怖活动的结果方面非常重要。 LASSA病毒已被确定为爆发出血热的原因，没有有效的治疗或治愈。因此，疫苗研究对于防止感染至关重要。我们为非人类灵长类动物中的埃博拉病毒感染制定了一种高效的疫苗策略。我们的实验室表明，可以通过一次接种腺病毒载体疫苗来产生对埃博拉病毒的免疫力，这对在埃博拉病毒爆发期间进行增强的环疫苗接种产生了重大影响。我们的目标是为LASSA使用类似的策略。